We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Janux Therapeutics (NASDAQ:JANX) has seen its share price rise 241% over the last year, deligh
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing
Jay Lichter, 10% Owner, Director, on June 03, 2024, sold 1,500,000 shares in Janux Therapeutics (JANX) for $82,125,000. Following the Form 4 filing with the SEC, Lichter has control over a total of 3,
Janux Therapeutics(JANX.US) Officer Sells US$45.04 Million in Common Stock
$Janux Therapeutics(JANX.US)$ Officer Reardon Tighe sold 822.72K shares of common stock on Jun 3, 2024 at an average price of $54.75 for a total value of $45.04 million.Source: Announcement What is st
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
JonesTrading analyst Soumit Roy maintains $Janux Therapeutics(JANX.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 26.0% and
Form 144 | Janux Therapeutics(JANX.US) Director Proposes to Sell 7.21 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Janux Therapeutics(JANX.US)$ Director Avalon BioVentures I, LP intends to sell 131.2K shares of its common stock on Jun 3, with a total market value of approximately $7
Form 144 | Janux Therapeutics(JANX.US) Director Proposes to Sell 38.01 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Janux Therapeutics(JANX.US)$ Director Avalon BioVentures SPV I, L.P. intends to sell 691.53K shares of its common stock on Jun 3, with a total market value of approxima
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday.Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and u
Express News | Janux Therapeutics Inc : Scotiabank Initiates Coverage With Sector Perform Rating and $47 Price Target
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $63
Buy Rating Affirmed for Janux Therapeutics With Revised Higher Price Target Amidst Strong Financials and Promising Clinical Trials
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Janux Therapeutics, Maintains $100 Price Target
We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate
Janux Therapeutics: Promising Early Data for EGFR-Targeted Therapies Warrants a Buy Rating
Insiders Made Right Decision To Sell As Janux Therapeutics Dips 11%
Insiders seem to have made the most of their holdings by selling US$1.3m worth of Janux Therapeutics, Inc. (NASDAQ:JANX) stock at an average sell price of US$45.94 during the past year. The company's
Janux Therapeutics | 10-Q: Quarterly report
Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.